Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec ; volume:15 ; number:1 ; day:20 ; month:7 ; year:2024 ; pages:1-11 ; date:12.2024
Nature Communications ; 15, Heft 1 (20.7.2024), 1-11, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Hubálek, František
Cramer, Christian N.
Helleberg, Hans
Johansson, Eva
Nishimura, Erica
Schluckebier, Gerd
Steensgaard, Dorte Bjerre
Sturis, Jeppe
Kjeldsen, Thomas B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-50477-9
- URN
-
urn:nbn:de:101:1-2410062122547.623638243258
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hubálek, František
- Cramer, Christian N.
- Helleberg, Hans
- Johansson, Eva
- Nishimura, Erica
- Schluckebier, Gerd
- Steensgaard, Dorte Bjerre
- Sturis, Jeppe
- Kjeldsen, Thomas B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Treatment responses with once-weekly teriparatide therapy for osteoporosis
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes